# Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment

> **NCT00078468** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 56 (—)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** PELITREXOL/AG-2037

## Key facts

- **NCT ID:** NCT00078468
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 56 (—)
- **Last updated:** 2006-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078468, "Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00078468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*